Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CanSino Biologics : GLOBALink | Argentina uses Chinese CanSino COVID-19 vaccine to immunize working-class neighborhoods

10/09/2021 | 12:02am EST
GLOBALink | Argentina uses Chinese CanSino COVID-19 vaccine to immunize working-class neighborhoods
2021-10

Vaccination with CanSino COVID-19 vaccine doses took place Friday in the La Carcova neighborhood of Jose Leon Suarez, a town in the northwest of Greater Buenos Aires, Argentina's capital.

The South American country recently began to immunize residents of working-class neighborhoods with vaccines developed by Chinese pharmaceutical company CanSino Biologics Inc.

Laura Fortuna, a nursing student helping to immunize residents, told Xinhua that in working-class neighborhoods the task is "to reach people who could not get vaccinated or who could not get to vaccination sites."

The CanSino vaccine is a single dose and that's very good, because people can complete their vaccination schedule at one time and there is no need for them to come back, Fortuna said. "So we use it a lot for low-income neighborhoods. They accept it better because it is a single dose."

To date, Argentina has received 600,000 doses of the single-dose CanSino viral vector vaccine, which is also easier to store than other vaccines.

CanSino has shown 65 percent efficacy in preventing symptomatic cases and over 90 percent efficacy in preventing severe cases.

Produced by Xinhua Global Service

Disclaimer

Cansino Biologics Inc. published this content on 08 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2021 04:01:09 UTC.


ę Publicnow 2021
All news about CANSINO BIOLOGICS INC.
11/15Argentina Recommends CanSino Bio's COVID-19 Vaccine for Booster Shots; Shares Rally 10%
MT
11/08Tech and healthcare firms drag Hong Kong shares lower
RE
11/08Shanghai stocks edge up as China exports data supports
RE
10/28CanSino Biologics Hits Over $62 Million in Q3 Profit
MT
10/28CanSino Biologics Inc. Reports Earnings Results for the Nine Months Ended September 30,..
CI
10/20CANSINO BIOLOGICS : Restricting travel over vaccine type could be discrimination, PAHO war..
RE
10/11CanSino Biologics Inc. Announces Appointment of Jing Wang as an Executive Director
CI
10/09CANSINO BIOLOGICS : GLOBALink | Argentina uses Chinese CanSino COVID-19 vaccine to immuniz..
PU
10/05OCUGEN : Bharat Biotech Enter Supply Deal for COVID-19 Vaccine Candidate; Commercializatio..
MT
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2021 6 444 M 1 016 M 1 016 M
Net income 2021 2 542 M 401 M 401 M
Net cash 2021 9 586 M 1 511 M 1 511 M
P/E ratio 2021 7,37x
Yield 2021 -
Capitalization 44 892 M 7 077 M 7 076 M
EV / Sales 2021 5,48x
EV / Sales 2022 3,32x
Nbr of Employees 726
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 116,76 CNY
Average target price 283,88 CNY
Spread / Average Target 143%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.-18.70%7 077
CSL LIMITED7.48%99 422
WUXI BIOLOGICS (CAYMAN) INC.-0.97%55 500
SAMSUNG BIOLOGICS CO.,LTD.10.65%51 558
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-4.14%34 479